209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy 7–9 November 2014, Heemskerk, The Netherlands-Reference-Cited by-同舟云学术

209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy 7–9 November 2014, Heemskerk, The Netherlands

Published:2015-07 Issue:7 Volume:25 Page:593-602
ISSN:0960-8966
Container-title:Neuromuscular Disorders
language:en
Short-container-title:Neuromuscular Disorders

Author:

Finkel Richard^ORCID,Bertini Enrico,Muntoni Francesco,Mercuri Eugenio

Funder

European Neuromuscular Centre

Association Française contre les Myopathies

Deutsche Gesellschaft für Muskelkranke

Muscular Dystrophy Campaign

Muskelsvindfonden

Prinses Beatrix Spierfonds

Schweizerische Stiftung für die Erforschung der Muskelkrankheiten

Telethon Foundation

Spierziekten Nederland

Cure SMA

SMA Foundation

Publisher

Elsevier BV

Subject

Genetics (clinical),Neurology (clinical),Neurology,Pediatrics, Perinatology and Child Health

Reference64 articles.

1. Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; Report of three expert workshops: TREAT-NMD/ENMC Workshop on outcome measures, 12th–13th May 2007, Naarden, The Netherlands; TREAT-NMD Workshop on outcome measures in experimental trials for DMD, 30th June–1st July 2007, Naarden, The Netherlands; Conjoint Institute of Myology TREAT-NMD Meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France

2. Solving the puzzle of spinal muscular atrophy: what are the missing pieces?;Tiziano;Am J Med Genet A,2013

3. A rare SMN2 variant in a previously unrecognized composite splicing regulatory element induces exon 7 inclusion and reduces the clinical severity of spinal muscular atrophy;Vezain;Hum Mutat,2010

4. A positive modifier of spinal muscular atrophy in the SMN2 gene;Prior;Am J Hum Genet,2009

5. How genetic modifiers influence the phenotype of spinal muscular atrophy and suggest future therapeutic approaches;Wirth;Curr Opin Genet Dev,2013

Cited by 166 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world multidisciplinary outcomes of onasemnogene abeparvovec monotherapy in patients with spinal muscular atrophy type 1: experience of the French cohort in the first three years of treatment;Orphanet Journal of Rare Diseases;2024-09-13

2. Spinal Muscular Atrophy Update in Best Practices;Neurology Clinical Practice;2024-08

3. Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges;Genes;2024-07-30

4. Impact of Nusinersen on Neurofilament, Creatinine Levels, and Motor Function in Pediatric Spinal Muscular Atrophy Rehabilitation: A Biomarker Analysis;Balneo and PRM Research Journal;2024-06-21

5. A Post-Marketing Surveillance Study of Nusinersen for Spinal Muscular Atrophy in Routine Medical Practice in China: Interim Results;Advances in Therapy;2024-05-09